Medicare forced to cover unproven devices for four years, no cost review

What it does

This bill creates a fast-track Medicare coverage pathway for medical devices that the FDA has designated as 'breakthrough' innovations. Once a device receives FDA priority review and meets clinical criteria, Medicare must cover it automatically for four years while the agency decides whether to make coverage permanent—bypassing the normal lengthy review process. Device makers apply to Medicare for 'breakthrough' status; the agency has six months to decide and must explain any rejection.

Why we flagged it

The bill's core mechanism is a mandatory four-year Medicare coverage guarantee for FDA-designated breakthrough devices, bypassing standard cost-effectiveness review. This is functionally a coverage entitlement for a defined device category, not a procedural reform.

What the text implies

• Medicare's standard coverage review (National Coverage Determination) is designed to assess cost-effectiveness and clinical necessity; this bill guarantees payment for four years based on FDA priority designation alone, potentially shifting cost-benefit analysis burden to the back end of the transitional period.
• Device manufacturers have strong incentive to seek FDA priority review (which is discretionary) knowing it triggers automatic Medicare coverage; this may accelerate FDA priority designations for devices with marginal clinical advantage over existing alternatives.

The full analysis lists 5 implications of this text.

Who stands to gain

medical device manufacturers (especially those with FDA breakthrough designations); device distributors and suppliers; hospitals and outpatient surgery centers (higher reimbursement certainty)